Prostate cancer is the most frequent cancer in men and a leading cause of cancer death.
Determining a patient's optimal therapy is a challenge, where oncologists must select a
therapy with the highest likelihood of success and the lowest likelihood of toxicity.
International standards for prognostication rely on non-specific and semi-quantitative tools,
commonly leading to over-and under-treatment. Tissue-based molecular biomarkers have
attempted to address this, but most have limited validation in prospective randomized trials …